A phase I , first in human ,randomized, double-blind, placebo-controlled study evaluating the safety, tolerability, and pharmacokinetics of ReS19-T in healthy subjects
Latest Information Update: 09 May 2022
At a glance
- Drugs ReS19 T (Primary)
- Indications Alzheimer's disease
- Focus Adverse reactions; First in man; Pharmacokinetics
- Sponsors reMYND
- 03 May 2022 Results published in the reMYND Media Release.
- 21 Oct 2021 Results presented in the reMYND Media Release.
- 21 Oct 2021 According to a reMYND media release, the single-ascending dose (SAD) phase completed enrollment of 58 healthy volunteers in the study and the multiple-ascending dose (MAD) phase has been initiated.